Argente J, Abusrewil S A, Bona G, Chiarelli F, Kelnar C J, Skordis N
Department of Paediatric Endocrinology, University Hospital Ninõ Jesús, Madrid, Spain.
J Pediatr Endocrinol Metab. 2001 Jul;14 Suppl 2:1003-8. doi: 10.1515/jpem-2001-s213.
Although it is difficult to reach international agreement on the definition of growth hormone deficiency (GHD) in children and adolescents, great efforts to do so have been made during the last two decades. A somewhat limited definition of GHD is: a combination of auxological, clinical, biochemical and metabolic abnormalities caused by lack or insufficiency of GH secretion that results in a decrease in the production of GH-dependent hormones and growth factors. Its aetiology is very complex. Therefore, specific studies must be performed during different periods of childhood (neonatal, prepubertal and pubertal periods). Auxological parameters, particularly growth velocity (GV), are still considered the best clinical measures for analysing human growth. The spectacular advances in our understanding of molecular biology during the past twenty years have allowed, and will continue to allow, a more and more precise diagnosis of the molecular anomalies of human growth. This will, in turn, allow changes caused by genetic lesions to be more efficiently distinguished from those due to nutritional, organic, tumoural, psychological or traumatic causes. Our knowledge of the molecular bases of undergrowth due to a deficiency in GH has developed as a result of the localisation and characterisation of human genes which code for proteins implicated in the hormonal regulation of growth. These genes include pituitary GH (GH1), pituitary transcription factor 1 (Pit-1), the prophet of Pit-1 (PROP-1), the pituitary transcription factor LHX3, the transcription factor HESX1 and the GH-releasing hormone receptor (GHRHr). In addition, magnetic resonance imaging is the best available imaging method for the evaluation of size and structure of the pituitary and the parasellar region.
尽管就儿童和青少年生长激素缺乏症(GHD)的定义达成国际共识存在困难,但在过去二十年里人们为此付出了巨大努力。GHD的一个较为有限的定义是:由生长激素(GH)分泌缺乏或不足导致的一系列体格学、临床、生化及代谢异常,进而引起GH依赖激素和生长因子分泌减少。其病因非常复杂。因此,必须在儿童期的不同阶段(新生儿期、青春期前和青春期)进行特定研究。体格学参数,尤其是生长速度(GV),仍然被认为是分析人类生长情况的最佳临床指标。在过去二十年里,我们对分子生物学的理解取得了惊人进展,这使得对人类生长分子异常的诊断越来越精确,并且将继续如此。反过来,这将使我们能更有效地区分由基因损伤引起的变化与由营养、器质性、肿瘤、心理或创伤性原因导致的变化。由于对参与生长激素调节的蛋白质进行编码的人类基因得以定位和表征,我们对因GH缺乏导致生长发育迟缓的分子基础的认识也得到了发展。这些基因包括垂体GH(GH1)、垂体转录因子1(Pit-1)、Pit-1的前体(PROP-1)、垂体转录因子LHX3、转录因子HESX1以及生长激素释放激素受体(GHRHr)。此外,磁共振成像(MRI)是评估垂体及鞍旁区域大小和结构的最佳影像学方法。